SEC Form 4 · accession 0001562180-15-000938
ARRAY BIOPHARMA INC · ARRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kyle Lefkoff
Director
Period of report
Oct 29, 2015
Accepted (ET)
Nov 2, 2015 · 6:31 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100412
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1 | $0.00 | Oct 29, 2015 | A | 5,000 | A | — | Oct 29, 2016 | Common Stock | 5,000 | 5,000 | D |
| Stock Option (Right to Buy) | $5.13 | Oct 29, 2015 | A | 25,000 | A | Oct 29, 2016 | Oct 29, 2025 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1Restricted Stock Units awarded to the reporting person for no additional cash consideration and represent a contingent right to receive one share of Array BioPharma Inc. common stock. The units vest and will be settled in stock on October 29, 2016, subject to continued service on Array's board of directors.